Navigation Links
UCB Announces Positive Results From Phase II Clinical Trial of Investigational Anti-Epilepsy Drug Brivaracetam
Date:12/3/2007

55.8% of patients, for 5mg/day, 20mg/day and 50mg/day, respectively,

compared to 16.7% for placebo.

-- Produced seizure freedom rates of 7.7% for 20 mg-50 mg/day, 8% for

5mg/day and 1.9% for placebo over the treatment period.

Patients in the second study (Abstract 3.218) were randomized to receive 50 mg/day, 150 mg/day, or placebo, administered twice-daily without titration over the 12 week treatment period. The findings for the study's primary endpoint-reduction in weekly seizure frequency over placebo-were not statistically significant. However, an analysis of the study's secondary endpoints demonstrated a clear difference between placebo and the 50 mg/day dose:
-- The median difference versus placebo for the percent reduction from

baseline in seizure frequency per week was 22.5%.

-- There was at least a 50% reduction in weekly seizure frequency from

baseline in 39.6% of patients, compared with 23.1% for placebo.

-- Seizure freedom rates of 9.4% were seen for 50mg/day, compared with

1.9% for placebo.

Retention rates in both studies were high and similar to placebo, with up to 98% of patients in the treatment group completing the studies. The most commonly reported adverse events were nausea, vomiting, fatigue, nasopharyngitis, anorexia, convulsion, dizziness, headache, somnolence, and insomnia. A dose-response relationship was not observed for the majority of adverse events analyzed in the studies.

Phase III clinical trials of brivaracetam as adjunctive therapy in patients with refractory partial onset epilepsy are already underway. Nearly 1,300 epilepsy patients, ages 16-70, will take part in three multicenter, multinational phase III trials. Two randomized, double-blind, placebo- controlled studies are designed to evaluate the efficacy and safety of brivaracetam (5, 20 and 50 mg/day or 20, 50 and 100 mg/day) over 12 weeks in patients with partial onset epilepsy, no
'/>"/>

SOURCE UCB, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... September 23, 2014 Trevera provides ... market. Included are Oracle Managed Services , ... supports all versions of Oracle E-Business Databases ... , Trevera has announced a significant enhancement ... need help with their software technology management, project ...
(Date:9/23/2014)... September 23, 2014 The Sloane ... in Singapore and Malaysia providing advanced aesthetic dermatology ... powder to its impressive skin care repertoire. Specially ... skin’s defences against the evil forces of aging, ... glow simultaneously, this new addition is revolutionizing the ...
(Date:9/23/2014)... The University of North Carolina ... In the Piedmont Triad, announced today that Dr. ... the Center for Translational Biomedical Research (CTBR). Zhang, ... after nearly a decade at the U.S. Department ... Division. , “Our goal is to build ...
(Date:9/23/2014)... Dennis Thompson HealthDay ... -- Coupled with worldwide marches demanding action on climate ... altered weather patterns in the United States may soon ... arrest and other heat-related illnesses are expected to increase ... lead author Dr. Jonathan Patz, director of the Global ...
(Date:9/23/2014)... Randy Dotinga HealthDay Reporter ... using cholesterol-lowering drugs while in the hospital for a hemorrhagic ... more than four times more likely to survive than people ... People taking the commonly used drugs known as statins ... or to a rehabilitation facility, the study reports. When ...
Breaking Medicine News(10 mins):Health News:Trevera, Inc adds Management Support to Services 2Health News:Trevera, Inc adds Management Support to Services 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 2Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 3Health News:The Sloane Clinic™ introduces a revolutionary BB powder to its impressive skin care repertoire 4Health News:Former Department of Energy Scientist Joins UNCG as Co-director of Biomedical Research Center 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 2Health News:Health Woes to Worsen Due to Climate Change, Study Warns 3Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 2Health News:Cholesterol-Lowering Drugs May Help After Certain Strokes 3
... finds dexmedetomidine caused less delirium, , , TUESDAY, Dec. ... on patients who are hooked up to mechanical ... worry that too much sedation might slow down ... , Now, researchers report that by substituting a ...
... January 7, Discovery Health Presents Five Nights of Active, Viewing ... ... FIT TO LIVE -, SILVER SPRING, Md., Dec. 11 ... annual,weight loss and general wellness campaign-launches with a four-part,television event following ...
... ANGELES, Dec. 11 AIDS Healthcare,Foundation (AHF) today ... Mike Huckabee, for his stubbornness and,recent failure to ... Senate campaign in which he called for people ... population. At the time, Huckabee,told Associated Press in ...
... Calls on Every Candidate from Every Party to ... WASHINGTON, Dec. 11 AIDS Action released a,statement ... rewrite,his HIV/AIDS platform to ensure that the policies ... and end stigma against people,living with HIV. "Governor ...
... combination of bortezomib (Velcade) and two other drugs is ... diagnosed with multiple myeloma, a team headed by Dana-Farber ... the American Society of Hematology. , The three-pronged regimen ... as Rev/Vel/Dex has achieved an overall response rate ...
... quality of life, researchers say , , TUESDAY, Dec. 11 ... constraint-induced movement therapy, some stroke patients can have significant ... a better quality of life, a new study finds. ... the less-affected hand. This forced them to use their ...
Cached Medicine News:Health News:Newer Sedative Might Help Patients on Ventilators 2Health News:Newer Sedative Might Help Patients on Ventilators 3Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 2Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 3Health News:Overweight Twins Battle the Bulge and Gain A New Lease on Life in National Body Challenge: Twins Edition on Discovery Health 4Health News:Huckabee's Defense of Earlier, Alarmist AIDS Stance Shows Unsuitability for Presidency, Says AHF 2Health News:AIDS Action Calls on Huckabee to Follow HIV/AIDS Science 2Health News:3-drug combination 'extremely promising' as first-line therapy for multiple myeloma 2Health News:Stroke Rehab Technique Has Lasting Results 2Health News:Stroke Rehab Technique Has Lasting Results 3
(Date:9/23/2014)... -- FDNA® ( http://www.fdna.com ) ... at the 2014 ASHG meeting, booth #1035, in ... the latest version of Face2Gene - the only available ... Face2Gene facilitates the detection of facial dysmorphic features and ... The new version of Face2Gene includes new features, ...
(Date:9/23/2014)... 2014 According to the ... (Radiofrequency, Ultrasound, Irreversible Electroporation, Cryotherapy, Microwave), Application (General ... Global Forecasts to 2019", published by MarketsandMarkets, studies the ... of 2014 to 2019. The market is expected ... of 9.6% from 2014 to 2019. ...
(Date:9/23/2014)... , Sept. 23, 2014  While proton therapy recently began in ... patent Ashya King , another case in the United ... as a young boy who was given just days to live now ... Logan Green of Arizona complained of ... journey of medical treatments that will conclude Sept. 23, when he completes ...
Breaking Medicine Technology:FDNA to Exhibit at ASHG2014 Presenting Face2Gene Integrated With London Medical Databases (LMD) Online 2Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 45-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 25-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 35-Year-Old Brain Cancer Patient Completes Proton Therapy, Awaits Kindergarten 4
... Reportlinker.com announces that a new market research ... Global Intraocular Lenses Industry ... the worldwide markets for Intraocular Lenses in US$ ... Lenses, and Foldable Intraocular Lenses. The report provides ...
... New Mexico Software, Inc. (OTC Bulletin ... and solutions that enable improved and faster communication within the healthcare ... diagnostic imaging services for the Heart Institute of the Caribbean ... Jamaica. HIC is now sending nuclear and other exams ...
Cached Medicine Technology:Reportlinker Adds Global Intraocular Lenses Industry 2New Mexico Software Launches Company's First International Telemedicine Service 2New Mexico Software Launches Company's First International Telemedicine Service 3
Heine Beta 200 Streak Retinoscope 2.5v...
System, English (Continental cord), 230 VAC....
Micro-mini fiber optic light....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Medicine Products: